Methotrexate (MTX) causes acute kidney injury (AKI), hepatotoxicity, and neutropenia . Glucarpidase, a recombinant enzyme, has been shown to rapidly cleave MTX into inactive metabolites within 15 minutes. However, the clinical impact of glucarpidase remains poorly studied. To address this gap, a study has investigated whether glucarpidase could improve clinical outcomes in 708 patients with MTX-induced AKI.
The study found that 25.8% of patients treated with glucarpidase experienced a 2.7-fold higher likelihood of kidney recovery and a faster recovery time (aHR – 1.88) than the control group. Additionally, glucarpidase reduced the risk of grade ≥2 neutropenia and transaminitis by 50% on day 7. However, no difference in time-to-death was observed between the treatment and control groups (aHR – 0.76). These findings indicate that glucarpidase may improve renal and extrarenal outcomes in…
